Reglan Tardive Dyskinesia Settlement: Understanding Ohio's Statute of Limitations

Latest update (2025-07)

FDA enforcement record (Ongoing): Presence of foreign tablets/capsules. [source]

From General Health Information to Occupational Exposure Concerns

For decades, general health and science information has served as the foundational layer for public understanding of medication risks and benefits. This broad educational heritage established baseline awareness that prescription drugs, while therapeutic, carry potential adverse effects requiring informed patient monitoring. Within this legacy framework, the focus remained on population-level guidance and clinical best practices. As this informational landscape evolved, a more targeted concern emerged: the occupational and environmental dimensions of specific pharmaceutical exposures. The transition from general health context to occupational exposure concern becomes particularly salient when examining long-term use of certain medications in workplace settings. Workers in industries requiring sustained gastrointestinal treatment, for instance, may face prolonged exposure to drugs like Reglan (metoclopramide), creating distinct risk profiles that differ from short-term clinical use. This pivot reframes the discussion from abstract health literacy to concrete exposure scenarios. The occupational lens introduces questions about cumulative dosage, duration of treatment protocols in industrial medicine, and the regulatory frameworks governing workplace medication management. It shifts attention from general patient populations to specific worker cohorts whose exposure patterns may amplify certain neurological risks, including tardive dyskinesia. This transition sets the stage for examining how legacy health information must adapt to address the particular vulnerabilities of occupational exposure contexts.

Reglan and Tardive Dyskinesia: A Medical Overview

Reglan (metoclopramide) is a medication approved for short-term use in adults with symptomatic gastroesophageal reflux or diabetic gastroparesis. However, its association with tardive dyskinesia (TD), a potentially irreversible movement disorder, has led to significant litigation, particularly regarding the adequacy of warnings and the statute of limitations in Ohio. Tardive dyskinesia is characterized by involuntary, repetitive movements of the face, tongue, trunk, or extremities. The clinical presentation can include grimacing, lip smacking, tongue protrusion, and rapid eye blinking. Diagnosis is based on clinical observation and history of exposure to dopamine-blocking agents like metoclopramide. The condition can be disfiguring and may persist even after the drug is discontinued (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Reglan works by blocking dopamine receptors in the brain, which increases gastric motility but also affects the extrapyramidal motor system. Prolonged blockade can lead to dopamine receptor supersensitivity, a mechanistic pathway thought to underlie TD. The risk of developing TD increases with longer treatment duration and higher cumulative doses (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The FDA-approved labeling includes a boxed warning stating that metoclopramide can cause TD, and that the drug is contraindicated in patients with a history of TD. It also advises using Reglan for the shortest duration necessary and reassessing the need for continued treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). For gastroesophageal reflux, the maximum recommended treatment duration is 12 weeks; for diabetic gastroparesis, treatment should also not exceed 12 weeks unless longer use is unavoidable, in which case routine monitoring for TD is recommended (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).

Ohio's Statute of Limitations for Reglan Claims

Despite these warnings, many patients were prescribed Reglan for extended periods, sometimes years, without adequate monitoring. The adequacy of warnings has been a central issue in litigation. Plaintiffs argue that the boxed warning, while present, was not sufficiently emphasized to prescribers or patients, and that the risk of TD was downplayed. The FDA label notes that metoclopramide may suppress or partially suppress signs of TD, potentially delaying diagnosis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). This masking effect can make it difficult for patients to recognize the onset of symptoms until the condition is advanced. In Ohio, the statute of limitations for product liability claims, including those related to Reglan and TD, is generally two years from the date the injury was discovered or should have been discovered. This discovery rule is critical because TD often develops insidiously. The timeline between exposure and documented harm can be months to years. Many patients do not associate their involuntary movements with Reglan use, especially if they stopped taking the drug years earlier. The statute of limitations may begin when a patient is diagnosed with TD by a physician, or when they reasonably should have known that Reglan caused their symptoms. However, Ohio courts have applied the discovery rule variably, and some claims have been dismissed if the plaintiff knew or should have known of the injury more than two years before filing. Settlement considerations for affected patients include the severity of TD, the duration of Reglan use, and the strength of evidence linking the drug to the injury. The FDA label explicitly states that Reglan can cause TD and that the risk increases with treatment duration (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). This labeling supports claims that the manufacturer knew or should have known of the risk. However, settlements may be influenced by whether the patient continued using Reglan after the boxed warning was added in 2009. Patients who developed TD after prolonged use may have stronger claims if they can show that the warnings were inadequate or that the drug was prescribed off-label for longer than recommended. The timeline between exposure and harm is a key factor. TD can appear during treatment, after dose reduction, or after discontinuation. The label warns that metoclopramide may suppress TD signs, so symptoms may only become apparent after the drug is stopped (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). This delayed presentation complicates the statute of limitations analysis. In Ohio, the clock may start when the patient first notices symptoms, even if they do not immediately seek medical attention. Patients should consult an attorney to determine whether their claim is timely.

Settlement Considerations and Legal Options

In summary, Reglan-induced tardive dyskinesia is a serious, potentially irreversible condition linked to prolonged use of metoclopramide. The FDA label provides clear warnings about the risk, but the adequacy of those warnings remains contested. Ohio's two-year statute of limitations, triggered by discovery of the injury, requires prompt action. Patients with TD should seek legal advice to evaluate their options, as settlements may be available for those who can demonstrate harm from inadequate warnings or excessive duration of use. References: - https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Reglan claims in Ohio?

In Ohio, the statute of limitations for product liability claims related to Reglan and tardive dyskinesia is generally two years from the date the injury was discovered or should have been discovered. This discovery rule is critical because TD often develops insidiously, and the clock may start when the patient first notices symptoms or receives a diagnosis.

Can I still file a claim if I stopped taking Reglan years ago?

Yes, you may still file a claim if you were diagnosed with tardive dyskinesia within the past two years or if you reasonably should not have known the cause earlier. However, Ohio courts apply the discovery rule variably, so it is important to consult an attorney promptly to assess your specific timeline.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Reglan exposure and a confirmed Tardive Dyskinesia diagnosis may request an independent eligibility review. [Begin Assessment]

References

FDA DailyMed - Reglan Label

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.